Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans

BACKGROUND: Few adults at high risk for atherosclerotic cardiovascular disease events use a PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitor). METHODS AND RESULTS: Using data from the US Veterans Health Administration, we identified veterans who initiated a PCSK9i between January 2018...

Descripción completa

Detalles Bibliográficos
Autores principales: Derington, Catherine G., Colantonio, Lisandro D., Herrick, Jennifer S., Cook, James, King, Jordan B., Rosenson, Robert S., Poudel, Bharat, Monda, Keri L., Navar, Ann Marie, Mues, Katherine E., Stevens, Vanessa W., Nelson, Richard E., Vanneman, Megan E., Muntner, Paul, Bress, Adam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174184/
https://www.ncbi.nlm.nih.gov/pubmed/33821686
http://dx.doi.org/10.1161/JAHA.120.019254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174184/
https://www.ncbi.nlm.nih.gov/pubmed/33821686
http://dx.doi.org/10.1161/JAHA.120.019254

Ejemplares similares